On March 4, 2026, Antengene Corporation and UCB entered into a global licensing agreement worth up to $1.18 billion to advance ATG-201. This experimental bispecific T-cell engager (TCE) therapy is specifically designed to target B cell-driven autoimmune diseases, marking a significant step into next-generation immunology treatments.
Under the financial terms, UCB will provide an upfront and near-term payment of $80 million. Antengene is also eligible for over $1.1 billion in future development and commercial milestones, plus tiered royalties on net sales. The deal grants UCB exclusive worldwide rights to develop, manufacture, and commercialize the ATG-201 modality.
ATG-201 functions by targeting the CD19 protein on B cells while simultaneously engaging the body’s T cells to eliminate pathogenic cells. A key feature of this therapy is its proprietary steric hindrance masking technology, which is engineered to improve safety by reducing the risk of cytokine release syndrome (CRS) and limiting T-cell exhaustion. Antengene plans to submit clinical trial applications in China and Australia in Q1 2026 and will conduct initial Phase I studies before transferring further global development to UCB.